Skip to content

A Phase 1 Study of IM-1021 in Participants with Advanced Cancer

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523160-20-00
Enrollment
23
Registered
2026-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced B-cell lymphomas, Advanced solid tumors

Interventions

None listed

Sponsors

Immunome Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 17, 2026